The Target MS Target Ibogaine Therapy Program, other conditions

Ambio Life Sciences has launched a clinical program to test ibogaine – an experimental and natural psychedelic – for neurodegenerative conditions such as multiple sclerosis (MS). The program aims to provide therapeutic support in a safe and medically supervised setting.

Now open to the public after a gentle launch earlier this year, this neuroregenerative program is designed for patients who are considering ibogaine as part of their care strategy. He has already treated 30 patients in a dedicated treatment establishment.

In addition to MS, the program is available for people with Parkinson’s disease, amyotrophic lateral sclerosis, cerebral vascular accidents, traumatic brain lesions and other conditions. The objective is to explore ibogaine as a potential support treatment.

“We create a safe and structured environment so that people with these conditions explore ibogaine, and we could be about to discover how ibogaine could support brain healing in a way that we do not fully understand today,” said Jonathan Dickinson, CEO and co-founder of Ambio, in a press release.

The volume of reduced lesions, the symptoms were held in 2 patients

In the MS, damage to the brain and spinal cord lead to a wide range of symptoms, including vision problems, poor coordination and balance, fatigue and pain. Available treatments can prevent new damage from occurring and slow the progression of the disease, but they generally cannot help patients find lost functions.

Ibogaine, currently illegal in the United States, is a psychedelic found in the root bark of the African plant of Iboga. It works by acting on receivers – for example, NMDA and opioid receptors – which play a role in brain activity. IBOGAINE also increases the production of molecules which help the nerve cells to survive and to form new connections.

As a clinician and Patient of MS, I experienced the complexity of these conditions and the limits of traditional treatments. The relief that some patients signals so far are motivating, including improvements in sight, mobility and neuropathic pain.

In a recent report, ibogaine has reduced the volume of lesions and attenuated the symptoms of the MP in two patients – one with a rechangent and the other with a progressive secondary Sep. After treatment, the two patients have also shown signs of improving brain analyzes suggesting new connections between nerve cells and the recreation of cerebral circuits.

“As a clinician and patient of MS, I experienced the complexity of these conditions and the limits of traditional treatments,” said Lyndsey Ryan, director of ambio therapy. “The relief that some patients signals so far is motivating, including improvements in sight, mobility and neuropathic pain.”

In the ambio program, a loading dosage is optimized for tolerability, followed by an extensive microdosage (taking very small doses). Weekly group sessions offer continuous support throughout the treatment period. In addition to providing safe access to ibogaine, the company will also collect real data.

Although the program does not promise a remedy, it gives patients a chance to participate in emerging therapy that could support a better quality of life and provide information to future research.

“Each participant helps us to learn what is possible,” said Ryan, who is also the main therapist of the program.

Recommended reading

Ibogaine has reserved “ Ms Hug ” for the patient

Country music artist Clay Walker and the NFL Brett Favre renowned temple were among the first to try the program. The two were diagnosed with neurodegenerative diseases – Walker with SEP in 1996 and Favre with Parkinson at the beginning of 2024.

“I was told about the ibogaine of a friend who finished the treatment and was blown away by the results,” said Favre. “Since my arrival in Ambio, I have felt a real change, especially in my sleep and my energy.”

Walker shared a similar experience. “My trip with ibogaine was extraordinary,” said Walker. “It relieved what we call” MS Hug “, this painful seal in the abdomen, and gave me clarity, concentration and real relief of stress. I hope that ibogaine can one day complete the treatment on patients that MS patients already have. ”

AMBIO works with the University of Dalhousie in Halifax, Canada, to explore how ibogaine works in people with neurodegenerative diseases, namely how it affects the biomarkers of neuroinflammation and models of Parkinson, MS and AVC diseases.

“This work can help define what could be like the future,” said Dickinson. “Even if we do not completely know what form it will still take, the preclinical research and the experience of each patient bring us closer to understanding how ibogaine can support Neurorepair.”